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Tuberculosis (TB) poses a huge burden of disease management in South Africa. The World Health 
Organisation (WHO) in 2018 estimated an incidence of 322000 cases of active TB.  Furthermore, in 
2014 the South African Department of Health estimated that 73% of TB patients were HIV co-infected. 
It is estimated that in the KwaMashu district of Durban alone, 39% of patients are HIV positive. The 
introduction of GeneXpert (GXP) testing in 2011 greatly improved the screening and prompt diagnosis 
of TB. This study serves as a quality improvement project, which will help identify predictors for a 
successful treatment outcome as outlined by the WHO case definitions.  The number of patients co-
infected with HIV at the KwaMashu Community Health Centre will also be reviewed, and further to 
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PART 1: BACKGROUND AND SIGNIFICANCE 
 
Mycobacterium Tuberculosis Complex is a group of acid-fast bacilli belonging to the 
Mycobacterium genus. The Mycobacterium genus includes the Mycobacterium tuberculosis 
complex and Non-tuberculosis Mycobacteria.  Mycobacterium tuberculosis (MTB) is the most 
common cause for disease within the Mycobacterium Tuberculosis complex. Other organisms 
within this group include Mycobacterium Bovis, Microti and Africanum. The Non-tuberculosis 
Mycobacteria include M. Kansasii, M Marinum and the Mycobacterium avium complex. (1)  
 
M. Tuberculosis is a rod-shaped aerobic bacterium. It is considered an acid-fast bacillus as it 
is not decolourised by acid alcohol. This is due to its high content of mycolic acids and long 
chained cross-linked fatty acids. In the cell wall these mycolic acids are linked to peptidoglycan 
and arabinogalactan which results in low permeability of the cell wall, reducing the potency of 
antibiotics.  
 
Lipoarabinomannan, another content of the cell wall, is involved in the pathogen – host 
interaction and aids with the survival of Mycobacterium Tuberculosis within macrophages. (1) 
Tests looking at the presence of mycobacterial lipoarabinomannan (LAM) antigen in urine 
have emerged as a possible diagnostic test in the fight against Mycobacterium Tuberculosis. 
(2) Mycobacterium Tuberculosis is transmitted predominantly via airborne droplet spread. 
Particles are 1-5 microns in diameter. (3)  MTB most commonly affects the lungs.  Extra-
pulmonary disease can also occur. Common extrapulmonary sites of involvement include the 
central nervous system (CNS), lymphatics, pleura, pericardium and bones. Isolated 
extrapulmonary TB is non-contagious. (4) This study will focus on pulmonary tuberculosis.  
 
In 2018 TB cases in South Africa were amongst the top two thirds of the global total with a 3% 
prevalence. (5) The disease continues to spread at an alarming rate. World Health Organization 
(WHO) statistics show that the incidence of TB has increased by 400% in 15yrs, with an 
estimated 322000 cases of active TB in 2018. (6)  193000 of the 322000 confirmed cases were 
co-infected with Human Immunodeficiency Virus (HIV). Latest South African government 




Provincially, in 2017 KwaZulu-Natal had an incidence of 58117 TB cases. There were 32855 
cases of new smear positive and 9527 cases of recurrent TB. The incidence of pulmonary TB 
per 100000 patients was 907. This was the second highest incidence in South Africa that year. 
Western Cape recorded the highest incidence with 911 cases. However, KwaZulu-Natal had 
the highest incidence of all TB cases with 1076 per 100000 patients. (7) 
 
 In 2018 the WHO revealed that 10 million people worldwide were diagnosed with TB. Of 
these patients 1.2 million (11%) were co-infected with HIV. The worldwide TB mortality rate 
that year was 1.2 million individuals.  251000 of these patients were HIV positive. (5) In South 
Africa TB was the leading cause of death between 2013 to 2015. (8) 
 
Furthermore, in South Africa there is an increased risk of infection due to household 
overcrowding, poor living conditions and migration. (9)  As Andreas Diacon a pulmonologist 
at Tygerberg Hospital states, “Our TB patients are practically living on top of each other, and 
many of them are malnourished, HIV positive and prone to alcohol abuse. Not only does 
crowding make it more likely that you’ll be exposed to TB, but substance abuse also weakens 
your immune system.” (10)  
 
South Africa finds itself in a unique position due to the fact that many people migrated from 
rural areas and settled in areas known as townships across the country. One such township is 
Khayelitsha in the Western Cape. The population is estimated at 450-500000. (9)  Forty five 
percent of the population is unemployed and approximately 30% live in informal housing. (11) 
The effects of poverty and overcrowding are evident if one looks at the TB statistics for this 
township.  In 2005 Khayelitsha had 1283 per 100000 newly reported TB cases. (9)  
 
This study will focus on patients from the KwaMashu area, a township similar to Khayelitsha 
in the Western Cape in certain respects. KwaMashu falls under the Northern central district of 
the eThekwini municipality in KwaZulu-Natal, South Africa. This district has a population of 
476727 people. It includes the suburbs of Ntuzuma, Inanda, Newlands East, Newlands West, 
Lindilani, and Parlock. In 2012-2013 the Northern district was considered a ‘hot spot’ for the 
prevalence of HIV, which was estimated at 39 %. (12) (13) 
 
The diagnosis of TB begins with good health education to recognise the symptoms of the 
disease. Patients presenting to primary health care facilities to screen for TB require accurate 
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diagnostic tests with good sensitivity and specificity. The KwaMashu Community Health 
Centre serves as the focal primary health care centre for many of the patients in this area. The 
community health centre serves an estimated population of  750000 people and also serves as 
a referral point for six satellite clinics and eleven mobile points. (14) The Ngubane Clinic 
within the KwaMashu health centre deals specifically with HIV patients on a daily basis. This 
study will focus on the predictors of a successful treatment outcome within this community.  
 
The National Guidelines focus on the following diagnostic tests: sputum microscopy, sputum 
culture and Polymerase chain reactions (PCR) based assays namely XPERT-MTB RIF and line 
probe assay (LPA). (12) (Figure:1)  
 
 
Figure:1 Gene Xpert MTB/RIF Algorithm (12) 
 
With regard to microscopy the two staining methods are the Ziehl-Neelsen and the Fluorescent 
Auramine staining.  Sputum microscopy demonstrates good specificity for TB. In HIV positive 
patients with non-cavitatary pulmonary disease or in patients with low bacillary load it 
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demonstrates a low sensitivity. Smear microscopy requires 10000 TB bacilli per ml of sputum 
to be detected positive. (15) Sputum microscopy does not distinguish between MTB complex 
and non-tuberculosis mycobacteria. 
 
There are currently two molecular tests available to diagnose TB. The Gene- Xpert MTB/RIF 
and the line probe assay. Both are PCR based tests. The GeneXpert MTB/RIF is used to rapidly 
diagnose TB and to demonstrate rifampicin resistance. It detects resistance by targeting specific 
mutations in the rpoBgene mutation.  Results may be available within two hours (15) 
 
In 2013 the WHO guidelines recommend Gene-Xpert MTB-RIF to be used in all adults with 
suspected TB. In South Africa Gene-Xpert has replaced sputum microscopy as the initial 
diagnostic test for Tuberculosis. The South African MTB-RIF programme is the largest in the 
world, accounting for more than half of all GXP cartridges procured globally in 2013. (16) 
 
GXP is more sensitive than smear microscopy. Only 150 bacilli per millilitre of sputum are 
needed to detect MTB. Smear microscopy will detect acid fast bacilli (AFB’s) in 30% of HIV 
positive MTB complex, culture positive patients and 60-70% of HIV negative MTB complex 
culture positive patients. The Gene-Xpert will detect 98% of smear positive, culture positive 
MTB complex cases and 60-70% of smear negative, culture positive patients. Importantly the 
GXP will also detect only MTB complex and not non tuberculosis mycobacteria. (17) The test 
also has a short turnover time of 2 hours and it can be processed on the following specimens: 
cerebral spinal fluid, sputum, body fluids and tissue samples. There is also a decreased risk of 
cross contamination as the test is carried out within a closed system (15) 
 
There are however, certain limitations of the GXP test. It cannot distinguish between live or 
dead bacilli and therefore cannot be used for follow up of patients on treatment. The test may 
be unsuccessful due to laboratory errors, test failure or invalid results. GXP is a molecular test 
which detects rifampicin resistance by testing for RPOB gene mutation. Rifampicin resistance 
detected may not correlate with physiological resistance leading to a disturbance between Xpert 
and culture results (15) (17) 
 
South Africa was the first country to replace smear microscopy with Xpert MTB/RIF. (16) 
Churchyard et al looked at Xpert MTB/RIF versus sputum microscopy as the initial diagnostic 
test for tuberculosis. Xpert MTB/RIF resulted in a 50% increase in the number of 
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bacteriological confirmed cases of tuberculosis. This resulted in more patients assessing 
treatment at an earlier stage. (16) Internationally, Sachdeva et al looked at the utilisation of 
Xpert MTB/RIF in rural public health settings and its effect on pulmonary TB, and MDR case 
findings in India. (18) The study found that the use of Xpert MTB/RIF resulted in greater 
notification rates of bacteriologically confirmed TB cases and importantly the implementation 
of the Xpert MTB/RIF resulted in an over fivefold increase in the detection rate of rifampicin 
resistant TB cases. (18)  
 
By April 2015 a total of 5 793 307 specimens were processed.  The TB positivity rate has been 
shown to be 16-18% in the first year, 13-14% in the second and third year and 11% in the 
fourth year. Therefore, the GeneXpert test has a higher sensitivity compared to microscopy 
with a TB positivity rate of only 8%.  In April 2015 KwaZulu-Natal had performed the greatest 
number of tests. In 2015 GeneXpert MTB/RIF statistics in KZN showed that 18284 tests 
confirmed MTB (8.45% total detected), 190800 specimens were undetected by the test and 
7206 specimens were unsuccessful. A total of 216290 sputum samples were sent for analysis. 
This large total in comparison to other provinces is most likely as a result of the number of 
GXP testing instruments that are placed in KwaZulu-Natal. (19) A further reason could be the 
higher burden of disease in KwaZulu-Natal. 
 
The LPA is the second molecular test used to diagnose TB. It also detects resistance to 
rifampicin and isoniazid. It can therefore reduce the time needed to diagnose MDR TB. It is 
also specific for MTB complex. However, like the Gene Xpert the test can only be used for 
diagnosis and not monitoring patients on treatment as it does not distinguish between live and 
dead bacilli. Also as mentioned with the Gene Expert, resistance detected may not correlate 
with physiological resistance.  The test is also dependent on smear results and can only be 
performed on smear positive or culture positive sputum specimens. The test itself is also labour 
intensive and contamination and human error can occur. (15) 
 
Even with advent of molecular based tests to detect MTB there still remains an important role 
for sputum culture results in the national diagnostic guidelines. Sputum culture is more 
sensitive than smear microscopy. It allows you to distinguish Mycobacterium tuberculosis from 
non-Mycobacterium Tuberculosis and to perform drug susceptibility testing. However, it is 
expensive and can only be reported as negative at the end of 6 weeks of incubation. Important 
indications for culture include the diagnosis of paucibacillary TB disease, drug susceptibility 
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testing in patients at high risk for MDR TB and in patients who remain smear positive at the 
end of the intensive or continuation phase of TB treatment. 
 
Culture is still required for HIV positive TB suspects who have a negative GXP test. It is also 
required for those patients diagnosed as rifampicin resistant on GXP who require drug 
susceptibility testing (DST) of other drugs, and in patients diagnosed as rifampicin sensitive 
TB on GXP who are failing treatment despite good adherence and therefore resistance to drugs 
other than rifampicin is suspected. (15) 
 
The National Tuberculosis management guidelines require patients to present at two months 
and five months to assess sputum microscopy for smear conversion (Figure 2). Reasons for 
non-conversion at the end of the intensive phase of TB treatment include the fact that non-
viable bacteria may remain visible by microscopy. Other potential explanations for non-
conversion of sputum smear at the end of the intensive phase of TB treatment are: poor 
supervision of the initial phase of therapy, poor patient adherence, poor quality of anti-TB 
drugs, under dosing of drugs, co-morbid conditions, drug-resistant M. tuberculosis that is not 
responding to first-line treatment and heavy initial bacillary load.(20)  Singla et al reported 
that, “patients with numerous bacilli on pre-treatment sputum smear examination had an almost 
six times greater risk of persistent sputum positivity than patients with few bacilli”. (21)(22) A 
further study also found that a higher pre-treatment smear grading and bilateral radiographic 
involvement were associated with the delay of smear conversion. (21) HIV status does not 










Figure:2 New Smear Positive, Drug sensitive TB Management (24) 
 
The WHO has defined six treatment outcomes which have been adopted into the South African 
National Tuberculosis Guidelines. (Figure:3) (25). It has been argued that these treatment 
outcomes are best suited for countries with a high incidence of Tb. (26) Ditah et al further state 
that some of the outcomes are non- inclusive of patient care where treatment management 
needs to be individualised. (26) This could result in patients being misclassified as per the 
guidelines. This is a limitation that would need to be addressed in future guidelines. This study 






Figure: 3 WHO Treatment outcomes for TB patients (excluding Rifampicin resistance or MDR-TB) (25) 
 
The WHO has also set a treatment success rate of at least 90% for persons diagnosed with TB. 
However, current data for new bacteriologically confirmed PTB cases indicates a decrease in 
treatment success rate from 86% in 2014 to 83% in 2017. (7,27) This study will focus on the 
predictors of successful treatment outcomes.  
 
Establishing reasons for unsuccessful treatment outcomes is important for reducing morbidity 
and mortality and for implementing more effective treatment strategies. (27) Plans for 
distributing clinical guidelines are often dependent on access to information and teaching of 
the guidelines. Initiatives that audit and provide feedback to individuals regarding their own 
performance are found to be more effective in implementing guidelines. (28) This would assist 
in promoting compliance to national TB guidelines. 
 
There are currently challenges faced in achieving successful treatment outcomes in TB patients 
in South Africa. One of the concerns is the lack of education among health care workers, 
regarding the treatment algorithm. The lack of education and training in many state facilities 
has severely hampered adherence to compliance. As Wondale et al state “treatment outcomes 
are fundamentally dependant on the adherence to the treatment protocol which is also 
dependant on the knowledge and commitment of patients and health care workers.” Patients 
living in poorly accessible and remote places could have a low level of knowledge that may 
contribute to poor treatment outcomes, (29) This is also relevant in a South African setting 
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where many patients live in remote, resource poor areas with a lack of education and health 
promotion. Furthermore, the lack of compliance to the TB algorithms and poor treatment 
outcomes has been compounded by the high frequency of staff rotations in hospital wards. (19) 
 
There are also many other factors that contribute to unsuccessful treatment outcomes. Frederick 
et al quoted a study done in Lusaka where 45% of the TB patients were non-complaint with 
drug treatment for various reasons such as poor transportation to the hospital and lack of family 
support. (30) Other patient factors identified included low socioeconomic class, poor 
accessibility to health care facilities, stigma attached to TB and associated illness. (30) Another 
South African study conducted in the Eastern Cape by Cramm et al in 2010 found that the 
stigma associated with a TB diagnosis may hinder a patients decision to seek medical assistance 
as well as remain compliant to TB treatment. The study also showed that TB/HIV co-infection 
may result in further stigmatization. (31)(32) Another important factor resulting in non-
adherence is an initial improvement after commencing TB treatment. This results in patients 
having a misconception that they have been cured and not continuing their course of treatment 
and follow up visits. (30) 
 
In a South African context, further challenges as highlighted by Wendy Stevens include 
improving linkages to care and focusing on populations at high risk. This includes patients 
from correctional services, miners and those diagnosed with MDR TB. (33)  Ditah et al also 
found that male sex, the elderly and sputum + PTB patients had worse treatment outcomes. 
(26) Another study conducted in Harar Town, Ethiopia also found that male sex and age > 65 
was associated with unsuccessful treatment outcomes. (34) This was further supported by a 
study conducted in Adis Adaba that showed that older age groups were associated with worse 
outcomes. (35) 
 
Possible reasons for poor outcomes in the elderly could include associated comorbidities in the 
elderly, physical deterioration due to the ageing process and less accessibility to health care 
facilities in the elderly as compared to the younger age groups. (35) Improving accessibility to 
health care for the elderly could be an important means of improving treatment outcomes. 
 
TB/HIV co-infection has also been associated with worse treatment outcomes. HIV 
predisposes to TB infection and also worsens outcomes. HIV/TB co-infection resulted in an 
increased incidence of treatment failure in a study done in Eastern Ethiopia. (36).  This was 
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also supported by other studies from Nairobi, Gambella Region, Dire Dare, Assela and Harar 
Town were TB/HIV co-infection resulted in worse treatment outcomes. (37,38,39,40,41). This 
could be due to the increased pill burden associated with HIV/TB co-infection as well as the 
increased mortality associated with the two conditions. (42). Strengthening health education 
and improving adherence to treatment with possible directly observed treatment regimens in 
this patient population could assist with improving treatment outcomes in a South African 
setting where we have a large population of patients that are co-infected with HIV and TB. 
 
Improving technical and clinical training among health care workers would also be important. 
Stevens also points out that the GeneXpert MTB/RIF diagnostic algorithm may require 
simplification. The diagnostic arm for HIV-positive patients found to be Xpert MTB/RIF 
negative may need to be reviewed. A simplified algorithm may result in better compliance to 
guidelines. (33) 
 
This study will aim to assess treatment outcomes as per the National Tuberculosis GeneXpert 
MTB/RIF guidelines. There is currently limited data regarding treatment outcomes as per the 
guidelines. It is hoped that this study will also serve as a quality improvement project by 
identifying the possible reasons for non-compliance and proposing possible further areas for 
developments within the guidelines. 
 
Quality Improvement projects can help improve the health care system in South Africa. As 
Muller states, “A person's health is one of the most important assets -therefore health care 
delivery should be of the highest quality.” He also states, “Quality in health care can be based 
largely on the quality of professional training and education.” (43) An example of a quality 
improvement project was undertaken by Scott et. al. that helped improve the diagnosis and 
management of TB patients in the Western Cape, South Africa. Data was collected for the 
study by conducting interviews with facility managers, auditing available equipment at various 
facilities and through the review of patient folders. The data was then reviewed and action plans 
were then formulated to address key problem areas. Successful strategies and lessons learnt 
were then shared to other health care workers. (44)  
 
It is hoped that the data from this study will improve TB management and treatment outcomes 
at the local community health centre in KwaMashu a township in Durban, South Africa. This 
area is currently a hotbed for TB and HIV co-infection. This study will help identify factors 
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associated with poor treatment outcomes. This would then improve the diagnosis and 
management of patients with TB and therefore aid with the fight against the Tuberculosis 
epidemic in the country. This study could then serve as a quality improvement project that can 
hopefully be extrapolated onto a bigger scale and promote similar studies to be undertaken at 


































1. Don L. Lango (ed.), Anthony S. Fauci (ed.), Dennis L. Kasper (ed.), Stephen L. 
Hauser (ed.), J. Larry Jaameson (ed.), Joseph Loscalzo (ed.). Harrisons’ Principals of 
Internal Medicine. Volume 1. 18th Edition. USA: McGraw Hill Companies; 2012 
2. WHO. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the 
diagnosis and screening of active tuberculosis in people living with HIV. WHO. 
Report Number: 2015,25. Available from: 
https://apps.who.int/iris/bitstream/handle/10665/193633/9789241509633_eng.pdf;jses
sionid=D81AA8FE7DA24A884A9CC15A91DF9D3D?sequence=1 
3. CDC. Introduction to the core curriculum on tuberculosis: What a clinician should 
know. Chapter 2. 6th Edition. CDC. 2013. Available 
from:https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf 
4. Connie A Haley. Extrapulmonary tuberculosis. [Presentation]. University of Florida, 
Southeast National Tuberculosis Centre. September 2013. Available from: 
https://docplayer.net/19228155-Extrapulmonary-tuberculosis-connie-a-haley-md-
mph-university-of-florida-southeast-national-tb-center-september-2013.html 




6. World Health Organisation. Global Tuberculosis Report. Geneva, 2014. Available 
from: https://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf 
7. Annabel Kanabus. TBFacts.org: TB Statistics for South Africa – National & 
provincial. Available from: http://www.tbfacts.org/tb-statistics-south-africa/  
8. STATS SA.Mortality and causes of death in South Africa, 2015: Findings from death 
notification, published 2017. Available from: 
http://www.statssa.gov.za/publications/P03093/P030932015.pdf 
9. Gerald Friedland, Anthony Harries, David Coetzee. Implementation Issues in 
Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies. The 
Journal of Infectious Diseases. 2007; 196(supplement 1): S114-S123. 
10. Charles W. Schmidt. Linking TB and the Environment: An Overlooked Mitigation 
Strategy. Environmental Health Perspectives. 2008 Nov; 116(11): A478–A485. 
11. David Coetzee, et al. Integrating tuberculosis and HIV care in the primary care setting 
in South Africa. Tropical Medicine and International Health. 2004; 9(6): A11–A15. 
12. Martin Gabela, Nicky Manivasen, Melanie Dazel, Ronald Dukie. District Health Plan 
2015/2016 Ethekwini Health District KwaZulu-Natal. Department of Health: Province 
of KwaZulu-Natal. 2015. Available from: 
http://www.kznhealth.gov.za/Strategic/DHP/2015-16/ethekwini.pdf 
13. Ethekwini Municipality. Inanda, Ntuzuma, KwaMashu (INK) Nodal Economic 
Development Profile KwaZulu Natal. Department: Provincial and Local Government, 





14. Department: Health, Province of KwaZulu Natal. KWAMASHU COMMUNITY 
HEALTH CENTRE. Available from: http://www.kznhealth.gov.za/kwamashuchc.htm  
15. Department of Health, Republic of South Africa. National Tuberculosis Management 
Guidelines 2014. ISBN: 978-1-920031-82-4, 2014. 
16. Gavin J Churchyard, et al. Xpert MTB/RIF versus sputum microscopy as the initial 
diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African 
roll-out of Xpert MTB/RIF. The Lancet Global Health. 2015; 3(8): e450–e457. 
17. Sebaka Molapo, Elizabeth Prentice, Linda Erasmus. GeneXpert MTB/RIF Frequently 
asked questions. National Health Laboratory Services. 2012. Available from: 
http://www.nhls.ac.za/assets/files/GeneXpert%20brochure.pdf  
18. Kuldeep Singh Sachdeva, Neeraj Raizada,,et al. Use of Xpert MTB/RIF in 
Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB 
Case Finding in India. PLOS One. 2015; 10(5): e0126065.  
19. National Health Laboratory Service. GeneXpert MTB/RIF progress report April 2015. 
NationalHealth Laboratory Service. 2015 Available from: 
http://www.nhls.ac.za/assets/files/GeneXpert%20Progress%20Report%20April%202
015%20Final.pdf  
20. Fabrice Nembot Djouma, Michel Noubom, Jérôme Ateudjieu, Hubert Donfack. Delay 
in sputum smear conversion and outcomes of smear-positive tuberculosis patients: a 
retrospective cohort study in Bafoussam, Cameroon. BMC Infectious Diseases. 
2015;15:139. 
21. Khalid Bouti, Mohammed Aharmim, Karima Marc, et al. Factors Influencing Sputum 
Conversion among Smear-Positive Pulmonary Tuberculosis Patients in Morocco.  
ISRN Pulmonology. 2013; 2013: 5 
22. R. Singla, M. M. Osman, N. Khan, N. Al-Sharif, M. O. Al-Sayegh, and M. A. Shaikh. 
Factors predicting persistent sputum smear positivity among pulmonary tuberculosis 
patients 2 months after treatment. International Journal of Tuberculosis and Lung 
Disease. 2003; 7(1): 58–64.  
23. Mbazi SenkoroEmail author, Sayoki G Mfinanga, Odd Mørkve. Smear microscopy 
and culture conversion rates among smear positive pulmonary tuberculosis patients by 
HIV status in Dar es Salaam, Tanzania. BMC Infectious Diseases. 2010; 10(210).  
24. The Aurum institute guideline: Managing TB in a new era of dignositics , 2016. 
Available from: https://www.hivsharespace.net/resource/managing-tb-new-era-
diagnostics-version-3 






26. Ditah IC, Reacher M, Palmer C, et alMonitoring tuberculosis treatment outcome: 
analysis of national surveillance data from a clinical perspective. Thorax 
2008;63:440-446 
27. Izudi J, Semakula D, Sennono R, et al Treatment success rate among adult pulmonary 
tuberculosis patients in sub-Saharan Africa: a systematic review and meta-analysis. 
BMJ Open 2019;9:e029400. doi: 10.1136/bmjopen-2019-029400 
28. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review 
of theoretic concepts, practical experience and research evidence in the adoption of 
clinical practice guidelines. Canadian Medical Association Journal. 1997; 157(4): 
408–416. 
29. Wondale, B. et al. A retrospective study on tuberculosis treatment outcomes at Jinka 
General Hospital, southern Ethiopia. BMC Res Notes 10, 680 (2017). 
30. Frederick AD Kaona, Mary Tuba, Seter Siziya, Lenganji Sikaona. An assessment of 
factors contributing to treatment adherence and knowledge of TB transmission among 
patients on TB treatment. BMC Public Health. 2004; 4(68).  
31. Nandzumuni V. Maswanganyi, Rachel T. Lebese, Ntsieni S. Mashau, Lunic B. 
Khoza. Patient-perceived factors contributing to low tuberculosis cure rate at Greater 
Giyani healthcare facilities.  Health SA Gesondheid. 2014; 19(1): 1-8.  
32. Cramm, J.M., Finkenflügel, H.J.M., Møller, V. & Nieboer, A.P., 2010. TB Treatment 
initiation and adherence in a South African community influenced more by 
perceptions than knowledge of tuberculosis. BMC Public Health. 2010; 10:72.  
33. Wendy Stevens. Beyond Implementation: Health systems strengthening and focus on 
high risk populations 2011-2014. [Presentation] WHO Geneva, Switzerland. 2 May 




34. Tola, A. et al. (2019). Tuberculosis Treatment Outcomes and Associated Factors 
among TB Patients Attending Public Hospitals in Harar Town, Eastern Ethiopia: A 
Five-Year Retrospective Study. Tuberculosis research and treatment, 2019, 1503219. 
35. Alem Y Gebre-Selassie S. Treatment outcomes of Tuberculosis Patients in selected 
Health Centres in Adis Adaba : a Five Year Retrospective Study. J Lung Health. 
2017; 1 (11) 95-12 
36. Zenebe T, Tefera E. Tuberculosis treatment outcome and associated factors among 
smear-positive pulmonary tuberculosis patients in Afar, Eastern Ethiopia: a 
retrospective study. The Brazilian Journal of Infectious Disease. 2016;20(6):635–6. 
pmid:27553661 
37. Tola A, Minshore KM, Ayele Y, Mekuria AN. Tuberculosis Treatment Outcomes and 
Associated Factors among TB Patients Attending Public Hospitals in Harar Town, 
Eastern Ethiopia: A Five-Year Retrospective Study. Hindawi Tuberculosis Research 
20 
 
and Treatment. 2019 Tola, Assefa & Minsamo, Kirubel & Ayele, Yohanes & 
Nigussie, Abraham. 2019. 1-11. 10.1155/2019/1503219. 
38. Ejeta E, Beyene G, Balay G, Bonsa Z, Abebe G. Factors associated with unsuccessful 
treatment outcome in tuberculosis patients among refugees and their surrounding 
communities in Gambella Regional State, Ethiopia. PLoS ONE. 2018;13(10). 
39. Tafesse K, Sisay S, Beyen TK, Tadesse L, Abera A, Siu GKH, et al. Treatment 
Outcomes of Tuberculosis at asella Teaching hospital, ethiopia: Ten Years’ 
retrospective aggregated Data. Front Med. 2018;5(38). 
40. Muture BN,et al. Factors associated with default from treatment among tuberculosis 
patients in nairobi province, Kenya: A case control study. BMC Public Health. 
2011;11(696). 
41. Amante TD, Ahemed TA. Risk factors for unsuccessful tuberculosis treatment 
outcome (failure, default and death) in public health institutions, Eastern Ethiopia. 
Ethiop J Health Dev. 2014;28(1). 
42. Tesema T, Seyoum D, Ejeta E, Tsegaye R (2020) Determinants of tuberculosis 
treatment outcome under directly observed treatment short courses in Adama City, 
Ethiopia. PLoS ONE 15(4): e0232468. 
43. Marie Muller. Quality Improvement in health care-a fundamental analysis and South 
African Perspective.Curationis.1996;19(4): 67-74. 
44. Vera Scott, Virginia Azevedo, Judy Caldwell. Improving access and quality of care in 

















































Treatment outcomes of Gene Xpert positive Tuberculosis patients in 
KwaMashu Community Health Centre, KwaZulu Natal South Africa-A 
retrospective review 
S Pillay, NP Magula    
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Understanding the clinical reasons for unsuccessful treatment outcomes for patients presenting 
with Tuberculosis (TB) is important for evaluating the effectiveness of TB control programs. 
Unsuccessful treatment outcomes for TB patients in this study is defined according to the  
World Health Organization (WHO)  treatment outcome definitions as patients who died, failed 
treatment, were lost to follow up, or not evaluated1. Here, we sought to investigate the 
relationship between TB treatment outcomes and its predictors in the KwaMashu region in 
Kwazulu-Natal (KZN). This area is currently a hotbed for TB and HIV co-infection. 
Method 
A retrospective study design was adopted to characterise adult patients diagnosed with Gene 
Expert (GXP) positive pulmonary TB at KwaMashu Community Health Centre from 1 January 
2016- 31 December 2017. TB treatment outcomes were assessed according to the WHO 
guidelines. Multiple logistic regression was used to explore determinants of unsuccessful 
treatment outcomes. 
Results 
Among the 596 TB patients diagnosed, the successful outcomes included 51.01% (n = 304) 
of cases cured, 6.38 % (n = 38) completed treatment.  The overall treatment success rate was 
57.38% whereas unsuccessful treatment outcomes were evident by 0.50% (n = 3) patients 
who died, 22.32% (n = 133) who were lost to follow-up and 10.91% (n = 65) who were 
unaccounted for. Sputum conversion at two months [AOR = 1.94 (1.27 – 2.96)] was 
significantly associated with unsuccessful treatment outcomes. 
Conclusion 
Treatment success rate was 57.38% which was below the success target set by the WHO. This 
proportion may be increased by regular follow-up of patients with poor treatment outcomes, 
by strengthening treatment adherence strategies and the provision of health information on TB 
treatment to patients from rural areas. This study also highlights the high rates of loss to follow 
up and unaccounted for patients during the six months of treatment follow up. This underscores 
the urgent need to aggressively follow-up treatment defaulters and design interventions to 
improve retention in care to improve treatment outcomes. 




What is known? 
In 2018, an estimated 10 million people globally were diagnosed with TB with the burden being 
heterogenous among countries. Of these patients 1.2 million (11%) were co-infected with Human 
Immunodeficiency Virus (HIV). The worldwide TB mortality was 1.2 million among HIV negative 
individuals and in addition 251000 deaths in HIV positive patients2.  The highest TB burden was 
reportedly in men (aged ≥ 15 years) with 57% being diagnosed in 2018. Comparatively women 
accounted for 32% of the cases  while children (aged < 15 years) accounted for 11%.2  Geographically, 
30 high TB burden countries collectively account for 87% of the word cases in 2018.3 South Africa has 
featured amongst the top two thirds of the global total with a 3% prevalence rate.2  
Considerable efforts have been mounted in the past decade to improve TB treatment outcomes and cure 
rates in South Africa. However, South Africa’s national treatment’s success rate of 76% is still below 
the WHO success rate of 90%. The country did not achieve the highly ambitious millennium 
development goals (MDG) target of halving its prevalence rate and mortality rate4. In 2017, South 
Africa reported an incidence of 322000 TB cases, of these cases 193000 (60%) were HIV positive. This 
highlights the need to continually strengthen existing TB control initiatives and also address patient 
comorbidities in the country. 
What is unknown? 
Over a 5-year period (2011-2015) there has been a steady decline in the incidence rate of TB in South 
Africa, with 690 per 100 000 cases reported in 2012 compared to the 520 per 100 000 in 20155. In 2015 
the province of KwaZulu Natal out of all 9 provinces ranked as having the second highest incidence 
rate of TB  with 685 per 100 000 population, however the most notable decline in the incidence rate has 
been in KwaZulu Natal over 5 years with a decrease from 1185 to 685 per 100 000 population between 
2011 and 2015 respectively6. In 2017 the incidence cases in KwaZulu Natal were 58117 with almost 
half, 23059 cases reported from eThekwini municipality.                                      
Despite a notable decline in the TB incidence rate both globally and within South Africa, TB still ranks 
in the top 10 causes of death worldwide7.  Between 2014 and 2016 TB was the leading cause of death 
in South Africa8. Being a curable disease, it still claims 4400 lives daily. In an attempt to control the 
global burden of disease in 2000, the United Nations Millennium Development Goals (MDGs) aimed 
to “Stop the spread and reverse the incidence of the global TB epidemic by 2015”, This goal was 
achieved between 2000-2013 and an estimated 37 million lives were saved9. Between 2000 and 2014 
the annual incidence rate of TB fell by 1.5%. The Stop TB Partnership which aimed by 2015 to reduce 
the TB prevalence and mortality rates by 50% compared to 1990 were not achieved worldwide10. 
As per the WHO, TB treatment outcomes should be assessed annually at both national and district 
levels11. We sought to evaluate treatment outcomes in a high-risk population group and identify reasons 
for defaulting follow up. This will assist in achieving the Stop TB 90/90/90 targets and also assist South 
Africa in achieving a 90% success rate. The 90/90/90 target ‘Is to identify at least 90% of all TB patients 
in the population that require treatment and place them on appropriate therapy, it aims to reach at least 
90% of the key population groups and reach at least 90% treatment success through affordable treatment 









This was a facility based retrospective study conducted in KwaMashu Community Health 
Centre. KwaMashu Community Health Centre is situated in KwaMashu township ward 45 of 
the eThekwini district, KwaZulu Natal province in South Africa. The CHC offers health 
services to the community of Kwamashu. It has a total of 25 beds. Currently the centre serves 
mainly the KwaMashu community and surrounding areas, with a catchment population of 
approximately 750 000 people. It is also a referral centre for six satellite clinics, eleven mobile 
clinics and other facilities in Phoenix, Inanda, Ntuzuma, Newlands East and Newlands West, 
Lindelani, and Parlock. In 2012-2013 the Northern district was considered a ‘hot spot’ for the 
prevalence of HIV, which was estimated at 39 %13,14. 
Study design and data collection 
A retrospective study design of adult patients (from 12 years and above) presenting at the 
KwaMashu community Health Center. Demographic and clinical data were retrieved from files 
of patients that presented between January 2016 to December 2017. Other data sources 
included provincial TB registers, patient treatment cards and laboratory registers. Individual 
patient notes were reviewed to supplement missing data or resolve discrepancies. TB treatment 
outcomes were reported and recorded according to the defined World Health Organization 
(WHO) outcome categories. 
De-identified patient data including socio-economic and clinical characteristics were collected 
on a pretested standardized form and entered in an Excel 2013 (Microsoft Corporation, 
Redmond, USA) spreadsheet.  Two individuals, independently cross-checked each entry for 
logical inconsistencies, invalid codes, omissions and improbable data by tabulating, 
summarizing and plotting variables with missing observations being excluded systematically. 
Operational definitions of key terms as defined by the WHO1 
Cured: An initially sputum smear-positive patient who is sputum smear/culture negative at 
or one month prior to, the completion of TB treatment and on at least one previous occasion 
at least 30 days prior  
Treatment completed: A patient who’s baseline sputum was positive and who has 
completed anti-TB treatment without evidence of failure but for whom sputum smear or 
culture results are not available in the last month of treatment and on at least one previous 
occasion. 
Treatment success: The sum of patients who were declared ‘cured’ and those who had 
‘completed’ treatment. 
Treatment failure: A patient whose sputum smear or culture is positive at the fifth month of 
treatment or later during the course of treatment. Excluded in this definition are patients 
found to have multi-drug resistant tuberculosis at any point of time during the treatment. 
Treatment defaulter/Lost to follow up: A patient who has been on treatment for at least 
four weeks and whose treatment was interrupted for two consecutive months or more. 
Died: A patient who died for any reason during the course of treatment. 
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Transfer out: A patient who started treatment and was transferred to another treatment unit 
and for whom the treatment outcome is not known at the time of evaluation of treatment results. 
 
 
Reporting of treatment outcomes/Operational definition 
Treatment outcomes among patients were reported as recommended by the WHO and the 
International Union Against Tuberculosis and Lung Disease (IUATLD)15. Six outcomes 
categories defining the treatment outcomes were used.  Successful outcomes were; cured and 
treatment completed whereas unsuccessful outcomes were treatment failure, loss to follow-up, 
death, and absence of evaluation. 
Cured (Patient completing full course treatment with negative bacteriology result in the last 
treatment month), treatment completed (PTB positive patient who has completed treatment), 
treatment failure (PTB positive whose bacteriology result remains positive at six months), loss 
to follow-up (PTB positive patient whose treatment is interrupted for two consecutive months 
or more after registration), death (A PTB positive patient who died due to TB or other course 
during TB treatment) 
Cured and treatment completed were summarized as treatment success whereas unsuccessful 




Data was analyzed in STATA 15 (Stata Corp LP, College Station, TX, USA). Summary 
statistics were presented, with continuous variables summarized with their mean and standard 
deviation (SD) whereas categorical variables summarized as counts and proportions (%). 
Simple logistic regression models were used to evaluate the relationship between unsuccessful 
treatment outcome (dependent variable) and the selected demographic and clinical variables. 
To determine the effect of predictors of unsuccessful treatment, unadjusted and adjusted odds 
ratios (AOR), 95% CI and p value were estimated for each predictor with a two-sided p value 
< 0.05 deemed statistically significant. 
Ethical Statement 
Ethical clearance and approval for the study was provided by the Biomedical Research 
Committee (BREC) in association with the University of KwaZulu Natal (BREC No 
BE509/16). Patients records were anonymized and de-identified before analysis with strict 








Demographic and clinical characteristics 
A total of 596 patients records were considered over the study period. Out of these cases 381 
(63.9%) were males and 215 (36.1%) were females. A total of 360 (60.4%) of the patients 
examined were HIV positive with 250 (42%) recorded as being on antiretroviral treatment 
(ART). The 30 – 39 age range had the highest percentage (34.2%) of TB cases, followed by 
the 20 – 29 age range with (32.2%), 40 – 49 age range with 15.9%, 50 – 59 range with 7.6%, 
below 20 with 6.0% and above 60 with 4.0%. (Table 1 and Table 2) 
Treatment outcomes 
Treatment outcomes of new smear positive pulmonary tuberculosis patients as per the standard 
criteria are shown in Table 3. Among the 596 patients included in the study 51.01% (n = 304) 
were cured, 6.38%  (n = 38) completed their treatment, 8.89% (n = 53) had treatment failure at 
five months, 22.32% (n = 133) were lost to follow-up, 0.50% (n = 3) died and 10.91% (65/596) 





















Abbreviations used: HIV – Human immunodeficiency virus; ART - Antiretroviral therapy 
 
Table 2: Clinical characteristics of participants by gender (n = 596) 
Patient’s Characteristics Patients 
Total: n (%) Male, % (95% CI) Female: % (95% CI) 
Age Below 20 36 (6.0) 3.4 (2.0 – 5.8) 10.7 (7.2 – 15.6) 
 20 – 29 192 (32.2) 29.4 (25.0 – 34.2) 37.2 (31.0 – 43.9) 
 30 – 39 204 (34.2) 37.0 (32.3 – 42.0) 29.3 (23.6 – 35.8) 
 40 – 49 95 (15.9) 17.8 (14.3 – 22.0) 12.6 (8.7 – 17.7) 
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 50 – 59 45 (7.6) 7.9 (5.6 – 11.1) 7.0 (4.2 – 11.3) 
 
 
Above 60 24 (4.0) 4.5 (2.8 – 7.1) 3.2 (1.6 – 6.7) 
HIV Status Positive 360 (60.4) 54.1 (49.0 – 59.0) 71.6 (65.2 – 77.3) 
 Negative 168 (28.2) 31.8 (27.3 – 36.6) 21.9 (16.8 – 27.9) 
 Unknown 68 (11.41) 14.2 (11.0 – 18.1) 6.5 (3.9 – 10.7) 
     
ART Yes 250 (42.0) 36.7 (32.0 – 41.7) 51.2 (44.5 – 57.8) 
 No 326 (54.7) 59.6 (54.5 – 64.4) 46.0 (39.5 – 52.8) 
 Unknown 20 (3.36) 3.7 (2.2 – 6.1) 2.8 (1.3 – 6.1) 
     
Diabetes mellitus No 529 (96.5) 97.2 (94.8 – 98.5) 95.4 (91.4 – 97.6) 
 Yes 18 (3.3) 2.9 (1.5 – 5.2) 4.1 (2.0 – 7.9) 




Negative 236 (39.6) 37.8 (33.0 – 42.8) 42.8 (36.3 – 49.5) 
Positive 251 (42.1) 45.1 (40.1 – 50.2) 36.7 (30.5 – 43.4) 
Unknown 109 (18.3) 17.1 (13.6 – 21.2) 20.5 (15.6 – 26.4) 



















In univariate analysis, unknown HIV status [OR = 2.60 (1.32 – 5.14)] and sputum conversion 
at two months [OR = 1.88 (1.27 – 2.78)] were associated with unsuccessful treatment outcome. 
Multivariate logistic regression analysis was used to explore treatment outcomes in the cohort 
study. The explanatory variables used in the regression model were gender, HIV status, ART, 
age, diabetes, and sputum conversion at two months. 
After adjusting for possible confounding factors such as gender, ART, age and diabetes, both 
unknown HIV status [aOR = 4.94 (1.83 – 13.36)] and sputum conversion at two months 
[aOR = 1.94 (1.27 – 2.96)] were significantly associated with increased odds of unsuccessful 




 Unadjusted Odds 
Ratio (95% CI) 
P-value Adjusted Odds Ratio P-value 
Gender     
   Female (Ref)     
   Male 1.04 (0.73, 1.49) 0.814 1.02 (0.66, 1.57) 0.941 
HIV Status     
Negative (Ref)     
Positive  1.25 (0.85, 1.82) 0.257 1.59 (0.86, 2.97) 0.142 
Unknown 2.60 (1.32, 5.14) 0.006 4.94 (1.83, 13.36) 0.002 
ART     
No (Ref)     
 Yes 0.84 (0.59 – 1.19) 0.333 0.70 (0.39, 1.23) 0.213 
 Unknown 0.67 (0.27 – 1.70) 0.402 0.35 (0.08, 1.42) 0.140 
Age     
Below 20 (Ref)     
20 – 29  0.98 (0.46, 2.08) 0.952 1.09 (0.43, 2.77) 0.864 
30 – 39 1.07 (0.50, 2.27) 0.862 1.11 (0.42, 2.93) 0.829 
40 – 49  0.94 (0.42, 2.11) 0.880 0.96 (0.34, 2.72) 0.943 
50 – 59 1.00 (0.39, 2.53) 1.000 1.23 (0.39, 3.93) 0.723 
Above 60 1.50 (0.47, 4.76) 0.491 2.30 (0.46, 11.4) 0.309 
Diabetes     
   No (Ref)     
   Yes 0.99 (0.37, 2.70) 0.996 0.72 (0.21, 2.46) 0.602 
Sputum conversion 2 
months 
    
   No (Ref)     
   Yes 1.88 (1.27, 2.78) 0.002 1.94 (1.27, 2.96) 0.002 
Abbreviations used: HIV – Human immunodeficiency virus; ART - Antiretroviral therapy  
 
DISCUSSION  
In this retrospective study we assessed TB treatment outcomes and the plausible determinants 
of unsuccessful outcomes. The study findings revealed a higher percentage of TB cases 
among the age groups of 20-29 and 30-39. This is consistent with studies done in 
Mpumalanga South Africa, Northeast and Central Ethiopia16,17,18. In our study the 
disproportionate burden in the age groups 20-29 and 30-39 could be as a result of greater 
mobility attendant to this demographic group occasioned by social and economic ambitions. 
A further contributing factor within the South African population could be due to the high 
prevalence of HIV co-infection among this age groups19. This is in contrast to studies in 
China, Cambodia and Vietnam where patients were  older than 55 years 20,21. Diabetes, 
concomitant malignancies and other co-morbidities in the elderly may predispose the older 
population to TB infection, Similarly there may be an increase in reactivation TB in the 
elderly22.Evidence alludes age to be an important factor in determining TB treatment 
outcomes23,24,25,26. However, no significant relationship was found between age and 
unsuccessful treatment outcome in our study.  
 
The majority of patients in our study were male (63.9%). This is consistent with other 
international studies conducted in Malaysia (70.24%)27, Cambodia, China, Vietnam 
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(69.1%)21, Ethiopia (61.3%)28 and Pakistan (51.7%)29 which have noted a similar trend. This 
could be attributed to differential susceptibility to TB due to biological orientation, lower 
female notification rates as a result of socio-economic and cultural barriers in health care 
access and higher risk in males due to their high-risk exposure, substance abuse and social 
engagement30. 
A large proportion of the patients in this study (60.4%) were HIV positive, consistent with 
HIV and TB coinfection rates in South Africa2. CD4 cell counts and viral loads were not 
known in many patients. Of note, only 40% of the HIV positive patients were on ART. This 
is of concern as according to The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
strategy to end HIV as a public health threat by 2030, 90% of all people living with HIV 
should know their HIV status, 90% of all patients diagnosed with HIV infection should 
receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy 
should have viral suppression by 202031. With the institution of the “test and treat” campaign 
in 2016 together with the national TB guidelines it is of concern that there is a large number 
of patients who are not on ART32,33. Our study also revealed that 11% of patients were also 
unaware of their HIV status. 
One of the determinants of an unsuccessful treatment outcome in this study was patients who 
did not know their HIV status. An opt out approach for HIV testing were HIV testing 
becomes a routine procedure as opposed to an opt in approach may result in less patients with 
HIV/TB co-infection being missed and allow for earlier diagnosis and treatment34,35. Patients 
diagnosed and initiated on treatment during the advanced stages of HIV could also have 
affected treatment outcomes36. 
Patients with higher CD4 cell counts and who are on ART have been shown to have more 
successful outcomes37. TB/HIV treatment in combination has been shown to improve 
treatment failure rates38. For patients who are HIV/TB coinfected and on ART the national 
rates have improved from 28% in 2011 to 89.1% in 20176. In comparison to the national 
standards, our study showed a large proportion of HIV positive patients who were not on 
treatment. Stronger initiatives aimed at HIV testing and commencement of treatment 
especially in TB/HIV high risk areas will need to be employed to improve TB treatment 
outcome rates.  
It is important to achieve and sustain acceptable levels of treatment success rates among TB 
patients39. The overall treatment success rate based on sputum smear positive TB cases was 
57.38%. The cure rate was 51.01%. The treatment success rate obtained in our study is 
relatively higher than 40.6% in Uganda40. However, this was still low compared to the WHO 
successful target rate of 90%12. Countries which have succeeded in making this target are 
Ethiopia (91.8%)41 and China (95.02%,93,9%)20,42. A systemic review and meta-analysis 
done in 7 Sub Saharan Africa countries showed a total TB success rate of 76%43. Two studies 
in Gauteng Province found success rates of 80%44 and 83.48%23. The low TB success rate 
within our study is an indication of generally under performing and failing TB programme in 
resource constrained areas.  
Other contributing factors might be our study’s sample size, the study period, HIV status and 
health care quality. A possible reason for the higher success rates obtained in the Gauteng 
studies may be the inclusion of all TB patients regardless of smear status, extrapulmonary TB 
and children. Patients who were transferred out were also excluded from the Gauteng study. 
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There was also a large default group in our cohort. A large pill burden associated with HIV 
and TB coinfection as well as patients starting to feel better after initial treatment 
commencement may have resulted in patients defaulting treatment. The KwaMashu district 
remains an impoverished community with a high rate of unemployment. Financial factors in 
terms of accessing health care facilities and attending follow up visits may have also 
contributed to patients defaulting treatment.  
A deeper understanding of factors associated with unsuccessful TB treatment outcomes can 
encourage appropriate interventions intended to reduce morbidity and mortality45. In this 
study, loss to follow-up 22.32% (n = 133) comprised a major portion of the unsuccessful 
outcome. Significantly lower rates were noted in a primary health care facility in 
Johannesburg (11%)44, Gauteng province (5.4%)23 and Ethiopia (8.5%)18 Age, gender and not 
being on ART has shown to increase the risk for lost to follow up.23 Several reasons related to 
our study participants and the health center may have contributed to the outcomes reported. It 
was noted in this study that patients were lost to follow up due to patient relocation, attempts 
were made by health care workers to trace patients through home visits and telephonic 
consultations. Social issues including alcohol and drug abuse as well as psychiatric 
conditions also contributed to patients being lost to follow up. 
Sputum conversion at two months was significantly associated with unsuccessful TB 
treatment outcomes. These findings are inconsistent with studies widely reported in Western 
Cape, South Africa46, Pakistan29 and India47. A possible reason for this could be that a large 
proportion of the unsuccessful outcomes in our study were due to patients who were lost to 
follow up. Patients who had achieved sputum conversion at two months may have believed 
that they have been cured and thereafter defaulted further treatment and follow up. Future 
treatment and monitoring programs and strategies should aim to ensure that patients are 
followed up for the entire six months and that patients adhere strictly to treatment regimes. 
 
Conclusion   
Tuberculosis continues to be a serious health concern both in South Africa and 
internationally. The study findings showed the treatment success rate to be below the WHO 
target of 90%. Information about determinants of unsuccessful treatment outcomes is 
important for TB control initiatives. Findings have implications for TB programmes and 
future studies. KwaMashu a township in Durban, South Africa is currently a hotbed for TB 
and HIV co-infection. It is hoped that this data will help improve TB management in resource 
constraint settings. This study will help identify factors affecting unsuccessful treatment 
outcomes and would then improve the management of patients with TB. It could also then 
serve as a quality improvement project that can hopefully be extrapolated onto a bigger scale 
and promote similar studies to be undertaken at other TB endemic areas and regions.  
 
Study limitations 
Study results should be applied with caution, due to inherent limitations of registry-based data. 
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Tuberculosis (TB) poses a huge burden of disease management in South Africa. The World 
Health Organisation (WHO) in 2013 estimated an incidence of 450,000 cases of active TB.  
Furthermore, in 2014 the South African Department of Health estimated that 73% of TB 
patients were HIV co-infected. It is estimated that in the KwaMashu district of Durban alone, 
39% of patients are HIV positive (10). The introduction of GeneXpert (GXP) testing in 2011 
greatly improved the screening and prompt diagnosis of TB.  However, little is known of the 
compliance to these management guidelines and the GXP algorithm. This study aims to test 
compliance to the GeneXpert sputum guidelines.  The number of patients co-infected with HIV 




In this retrospective descriptive study the following categorical variables have been 
identified: age, gender, baseline sputum sample, two month sputum sample, five 
month sputum sample, HIV status, Diabetic status, compliance to sputum guidelines 
(Gene Xpert MTB RIF algorithm). 
Independent variables include age, gender, baseline sputum sample, two month 
sputum sample, and five month sputum sample, HIV status and Diabetic status. The 
Dependent variable is compliance to sputum guidelines. Possible confounding 
variables are gender and age. Due to the source and nature of the data collection it is 
expected that missing values due both to patients who are lost to follow- up and human 
error will arise.  To account for these values occurring not at the baseline level we will 
conduct imputation. A logistic regression using the aforementioned variables will be 










This study serves as a quality improvement project.  As an initial step a hypothesis test will be 
conducted. This will form a clinical audit. The data will be collected by means of a question 
survey which will be completed by the staff at KwaMashu CHC who are involved in the TB 
sputum collections and data recording. This survey will test the staffs’ knowledge of the GXP 
sputum guidelines. If the hypothesis test is found true it will serve as motivation for conducting 
this study and further quality improvement at KwaMashu CHC. 
 
If however, the hypothesis test is found to be false and that in fact the staff at KwaMashu CHC 
are well educated on the GXP sputum guidelines, if required, further investigation should be 
undertaken to evaluate the reasons for non-compliance to guidelines. 
 
Research Question/Hypothesis 
The Staff at KwaMashu CHC lack the knowledge of the Gene Xpert MTB/RIF algorithm and 




SPECIFIC AIM AND OBJECTIVES 
Specific Aims 
To evaluate compliance to the National Tuberculosis Management Guidelines: Gene Xpert 
MTB/RIF Algorithm for patients presenting with GXP sputum positive Tuberculosis. 
 
This Aim will be investigated by evaluating the following objectives: 
 
 The number of patients who are Gene Xpert Positive who get a smear at base. 
 The proportion of patients who have sputum collected at two months and 5 months. 
 The proportion of patients who have sputum collected at two months and 5 
months who undergo smear conversion or develop drug resistance 
Tuberculosis. 
 The proportion of patients diagnosed GXP positive Tuberculosis who are co-infected 
with HIV. 
 The number of HIV co-infected patients who achieve smear conversion or 
develop drug resistant Tuberculosis. 
 To evaluate the knowledge of the GXP guidelines by the staff at KwaMashu 
Community Health Centre. 




BACKGROUND AND SIGNIFICANCE 
 
Mycobacterium Tuberculosis Complex is a group of acid fast bacilli belonging to the 
Mycobacterium genus. The Mycobacterium genus includes the Mycobacterium tuberculosis 
complex and Non-tuberculosis Mycobacteria.  Mycobacterium tuberculosis (MTB) is the most 
common cause for disease within the Mycobacterium Tuberculosis complex. Other organisms 
within this group include Mycobacterium bovis, microti and africanum. The Non-tuberculosis 
Mycobacteria include M. Kansasii, M Marinum and the Mycobacterium avium complex. (1)  
M. Tuberculosis is a rod shaped aerobic bacterium. It is considered an acid fast bacillus as it 
is not decolourised by acid alcohol. This is due to its high content of mycolic acids and long 
chained cross linked fatty acids. In the cell wall these mycolic acids are linked to peptidoglycan 
and arabinogalactan which results in low permeability of the cell wall, reducing the potency of 
antibiotics.  
 
Lipoarabinomannan, another content of the cell wall, is involved in the pathogen – host 
interaction and aids with the survival of Mycobacterium Tuberculosis within macrophages. (1) 
Tests looking at the presence of mycobacterial lipoarabinomannan (LAM) antigen in urine 
have merged as a possible diagnostic test in the fight against Mycobacterium Tuberculosis. 
(2) Mycobacterium Tuberculosis is transmitted predominantly via airborne droplet spread. 
Particles are 1-5 microns in diameter. (3)  MTB most commonly affects the lungs.  Extra-
pulmonary disease can also occur. Common extrapulmonary sites of involvement include the 
central nervous system (CNS), lymphatics, pleura, pericardium and bones. Isolated 
extrapulmonary TB is non-contagious. (4) This study will focus on pulmonary tuberculosis.  
 
In 2013 South Africa had the third highest incidence of TB internationally. The disease 
continues to spread at an alarming rate. WHO statistics show that the incidence of TB has 
increased by 400% in 15yrs, with an estimated 450000 cases of active TB in 2013.  270000 
of the 450000 cases were co-infected with HIV.  Latest South African government statistics 
have revealed TB HIV co-infection to be as high as 73 %.( 9) 
 
Provincially, in 2006 KwaZulu-Natal had a total of 104705 cases of TB. Of that total 88271 
were PTB cases. There were 32855 cases of new smear positive and 9527 cases of recurrent 
TB. The incidence of pulmonary TB per 100000 patients was 907. This was the second highest 
incidence in South Africa that year. Western Cape recorded the highest incidence with 911 
cases. However, KwaZulu-Natal had the highest incidence of all TB cases with 1076 per 
100000 patients. (9) 
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 In 2014 the World Health Organization (WHO) revealed that 9.6 million people worldwide 
were diagnosed with TB. Of these patients 1.2 million were co-infected with Human 
Immunodeficiency Virus (HIV). The worldwide TB mortality rate that year was 1.5 million 
individuals.  400000 of these patients were HIV positive. (8) In South Africa TB was the leading 
cause of death between 2010 to 2012 for the population group 15 to 49. (9) 
 
Furthermore, in South Africa there is an increased risk of infection due to household 
overcrowding, poor living conditions and migration. (5)  As Andreas Diacon a pulmonologist 
at Tygerberg Hospital states, “Our TB patients are practically living on top of each other, and 
many of them are malnourished, HIV positive and prone to alcohol abuse. Not only does 
crowding make it more likely that you’ll be exposed to TB, but substance abuse also weakens 
your immune system.” (6)  
 
South Africa finds itself in a unique position due to the fact that many people migrated from 
rural areas and settled in areas known as townships across the country. One such township 
is Khayelitsha in the Western Cape. The population is estimated at 450-500000. (5)  Forty five 
percent of the population is unemployed and approximately 30% live in informal housing. (7) 
The effects of poverty and overcrowding are evident if one looks at the TB statistics for this 
township.  In 2005 Khayelitsha had 1283/100000 population of newly reported TB cases. (5)  
 
This study will focus on patients from the KwaMashu area, a township similar to Khayelitsha 
in the Western Cape in certain respects. KwaMashu falls under the Northern central district of 
the Ethekwini municipality in KwaZulu-Natal, South Africa. This district has a population of 
476727 people. It includes the suburbs of Ntuzuma, Inanda, Newlands East and Newlands 
West, Lindilani, and Parlock. In 2012-2013 the Northern district was considered a ‘hot spot’ 
for the prevalence of HIV, which was estimated at 39 %. (10) (11) 
 
The diagnosis of TB begins with good health education to recognise the symptoms of the 
disease. Patients presenting to primary health care facilities to screen for TB require accurate 
diagnostic tests with good sensitivity and specificity. The KwaMashu Community Health 
Centre serves as the focal primary health care centre for many of the patients in this area. The 
community health centre serves a population of about 750000 people and also serves as a 
referral point for six satellite clinic and eleven mobile points. (28) The Ngubane Clinic within 
the KwaMashu health centre deals specifically with HIV patients on a daily basis. This study 




The National Guidelines focus on the following diagnostic tests: sputum microscopy, culture 
and Polymerase chain reactions (PCR) based assays namely XPERT-MTB RIF and line probe 
assay (LPA). (12) Once these diagnostic tests have been used the study will hope to ascertain 
whether the compliance thereafter to national guidelines is being adhered to. 
 
With regard to microscopy the two staining methods are the Ziel-Neelsen and the Fluorescent 
Auramine staining.  Sputum microscopy demonstrates good specificity for TB. In HIV positive 
patients with non-cavitatory pulmonary disease or in patients with low bacillary load it 
demonstrates a low sensitivity. Smear microscopy requires 10000 TB bacilli per ml of sputum 
to be detected positive.  (12) Sputum microscopy does not distinguish between MTB complex 
and non-tuberculosis mycobacteria. 
 
There are currently two molecular tests available to diagnose TB. The Gene- Xpert MTB/RIF 
and the line probe assay. Both are PCR based tests. The GeneXpert MTB/RIF is used to 
rapidly diagnose TB and to demonstrate rifampicin resistance. It detects resistance by 
targeting specific mutations in the rpoBgene mutation.  Results may be available within two 
hours (12) 
 
In 2013 the WHO guidelines recommend Gene-Xpert MTB-RIF to be used in all adults with 
suspected TB. In South Africa Gene-Xpert has replaced sputum microscopy as the initial 
diagnostic test for Tuberculosis. The South African MTB-RIF programme is the largest in the 
world, accounting for more than half of all GXP cartridges procured globally in 2013(13) 
 
GXP is more sensitive than smear microscopy. Only 150 bacilli per millilitre of sputum are 
needed to detect MTB. Whereas smear microscopy will detect acid fast bacilli (AFB’s) in 30% 
of HIV positive MTB complex, culture positive patients and 60-70% of HIV negative MTB 
complex culture positive patients. The Gene-Xpert will detect 98% of smear positive, culture 
positive MTB complex cases and 60-70% of smear negative, culture positive patients. 
Importantly the GXP will also detect only MTB complex and not non tuberculosis 
mycobacteria. (14) The test also has a short turnover time of 2 hours and it can be processed 
on the following specimens: cerebral spinal fluid, sputum, body fluids and tissue samples. 
There is also a decreased risk of cross contamination as the test is carried out within a closed 
system (12) 
 
There are, however, certain limitations of the GXP test. It cannot distinguish between live or 
dead bacilli and therefore cannot be used for follow up of patients on treatment. The test may 
be unsuccessful due to laboratory errors, test failure or invalid results. GXP is a molecular test 
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which detects rifampicin resistance by testing for RPOB gene mutation. Rifampicin resistance 
detected may not correlate with physiological resistance leading to a disturbance between 
Xpert and culture results (12) (14) 
 
South Africa was the first country to replace smear microscopy with Xpert MTB/RIF. (13) 
Churchyard et al looked at Xpert MTB/RIF versus sputum microscopy as the initial diagnostic 
test for tuberculosis. Xpert MTB/RIF resulted in a 50% increase in the number of 
bacteriological confirmation of tuberculosis. This resulted in more patients assessing 
treatment at an earlier stage. (13) Internationally, Sachdeva et al looked at the use of Xpert 
MTB/RIF in decentralized public health settings and its effect on pulmonary TB, and MDR 
case finding in India. (15) The study found that the implementation of Xpert MTB/RIF resulted 
in greater notification rates of bacteriologically confirmed TB cases and importantly the 
implementation of the Xpert MTB/RIF resulted in over fivefold increase in the detection rate of 
rifampicin resistant TB case detection. (15)  
 
The LPA is the second molecular test used to diagnose TB. It also detects resistance to 
rifampicin and isoniazid. It can therefore reduce the time needed to diagnose MDR TB. It is 
also specific for MTB complex. However, like the Gene Xpert the test can only be used for 
diagnosis and not monitoring patients on treatment as it does not distinguish between live and 
dead bacilli. Also as mentioned with the Gene Expert, resistance detected may not correlate 
with physiological resistance.  The test is also dependent on smear results and can only be 
performed on smear positive or culture positive sputum specimens. The test itself is also 
labour intensive and contamination and human error can occur. (12) 
 
Even with advent of molecular based tests to detect MTB there still remains an important role 
for sputum culture results in the national diagnostic guidelines. Sputum culture is more 
sensitive than smear microscopy. It allows you to distinguish Mycobacterium tuberculosis from 
non-Mycobacterium Tuberculosis and to perform drug susceptibility testing. However it is 
expensive and can only be reported as negative at the end of 6 weeks of incubation. 
Important indications for culture include the diagnosis of paucibacillary TB disease, drug 
susceptibility testing in patients at high risk for MDR TB and in patients who remain smear 
positive at the end of the intensive or continuation phase of TB treatment. 
 
Culture is still required for HIV positive TB suspects who have a negative GXP test. It is also 
required for those patients diagnosed as rifampicin resistant on GXP who require drug 
suscessability testing (DST) of other drugs, and in patients diagnosed as rifampicin sensitive 
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TB on GXP who are failing treatment despite good adherence and therefore resistance to 
drugs other than rifampicin is suspected. (12) 
 
The National tuberculosis management guidelines require patients to present at two months 
and five months to assess sputum microscopy for smear conversion. Reasons for non-
conversion at the end of the intensive phase of TB treatment include the fact that non-viable 
bacteria may remain visible by microscopy. Other potential explanations for non-conversion 
of sputum smear at the end of the intensive phase of TB treatment are: poor supervision of 
the initial phase of therapy, poor patient adherence, poor quality of anti-TB drugs, under dosing 
of drugs, co-morbid conditions, drug-resistant M. tuberculosis that is not responding to first-
line treatment and heavy initial bacillary load.(24)  Singla et al reported that, “patients with 
numerous bacilli on pre-treatment sputum smear examination had an almost six times greater 
risk of persistent sputum positivity than patients with few bacilli”. (25)(27) A further study also 
found that a higher pre-treatment smear grading and bilateral radiographic involvement were 
associated with the delay of smear conversion. (25) HIV status does not seem to influence 
sputum smear conversion rates. (26) 
 
 
This study will focus on the compliance to sputum guidelines as set out in the National 
Tuberculosis Guidelines. There are many challenges faced in implementing national health 
guidelines. As Davis and Taylor-Vaisey described in a systematic review, “the characteristics 
of health professionals, practice setting, regulatory environment, incentives and patient factors 
play a role in converting guidelines into practice”.(16)(17) Similarly, Cabana et al also found 
that the ignorance of the existence and content of guideline’s existence common reasons for 
noncompliance. (17) (18) 
 
This study also intends to serve as a quality improvement project. Plans for distributing clinical 
guidelines are often dependent on access to information and teaching of the guidelines. 
Initiatives that audit and provide feedback to individuals regarding their own performance are 
found to be more effective in implementing guidelines. (17) This would assist in promoting 
compliance to national TB guidelines. 
 
There are currently challenges faced in implementing the GXP guidelines in South Africa. One 
of the concerns is the lack of education among health care workers, regarding the GXP testing 
algorithm. The lack of education and training in many state facilities has severely hampered 
adherence to compliance. Furthermore, the lack of compliance to the TB algorithms has been 




There is currently a lack of data on patient factors for non-compliance to GXP sputum 
guidelines. However, if one looks at patient factors responsible for non-compliance to TB 
treatment guidelines one would expect the reasons to be similar. Frederick et al quoted a 
study done in Lusaka where 45% of the TB patients are non-complaint with drug treatment for 
various reasons such as poor transportation to the hospital and lack of family support. (20) 
Other Patient factors identified include low socioeconomic class, poor accessibility to health 
care facilities, stigma attached to TB and associated illness. (20) Another South African study 
conducted in the Eastern Cape by Cramm et al. (2010) found that the associated stigma might 
influence TB patients’ behaviour in seeking help and adhering to TB treatment. In the same 
study, the findings showed that people infected with TB had a tendency to hide their TB status 
out of fear of being stigmatised. This might be influenced by its association with HIV infection. 
(21)(22) Another important factor resulting in non-adherence is an initial improvement after 
commencing TB treatment. This results in patients having a false belief that they have been 
cured and not continuing their course of treatment and follow up visits. (20) 
 
In a South African context, further challenges as highlighted by Wendy Stevens include 
improving linkages to care, and focusing on populations at high risk. This includes patients 
from correctional services, miners and those diagnosed with MDR TB. Improving technical 
and clinical training would also be important. Stevens also points out that the GeneXpert 
MTB/RIF diagnostic algorithm may require simplification. The diagnostic arm for HIV-positive 
patients found to be Xpert MTB/RIF negative may need to be reviewed. A simplified algorithm 
may result in better compliance to guidelines. (23) 
 
Despite the challenges faced there has been great progress with the GeneXpert MTB/RIF 
programme.  By April 2015 a total of 5 793 307 specimens were processed.  The TB positivity 
rate has been shown to be 16-18% in the first year, 13-14% in the second and third year and 
11% in the fourth year. This result shows the GeneXpert tests’ higher sensitivity over 
microscopy with a TB positivity rate of only 8%.  In April 2015 KwaZulu-Natal had performed 
the greatest number of tests. In 2015 GeneXpert MTB/RIF statistics in KZN showed that 18284 
tests confirmed MTB (8.45% total detected), 190800 specimens were undetected by the test 
and 7206 specimens were unsuccessful. A total of 216290 sputum samples were sent for 
analysis. This large total in comparison to other provinces is most likely as a result of the 
number of GXP testing instruments that are placed in KwaZulu-Natal. (19) A further reason 




This study will aim to test compliance to the national tuberculosis GeneXpert MTB/RIF 
guidelines. There is currently a paucity of data regarding compliance to these guidelines. It is 
hoped that this study will also serve as a quality improvement project by identifying the 
possible reasons for non-compliance and proposing possible further areas for developments 
within the guidelines. 
 
Quality Improvement projects can help improve the health care system in South Africa. As 
Muller states, “A person's health is one of the most important assets -therefore health care 
delivery should be of the highest quality.” He also states, “Quality in health care can be based 
largely on the quality of professional training and education.” (30) An example of a quality 
improvement project was undertaken by Scott et aI that helped improve the diagnosis and 
management of TB patients in the Western Cape, South Africa. Data was collected for the 
study by conducting interviews with facility managers, auditing available equipment at various 
facilities and through the review of patient folders. The data was then reviewed and action 
plans were then formulated to address key problem areas. Successful strategies and lessons 
learnt were then shared to other health care workers. (31) It is hoped that this study will serve 
as a quality improvement project to help improve the compliance to the GXP sputum 







RESEARCH DESIGN AND METHODS 
Overview 
The study is a retrospective descriptive study. In this section, a brief overview of the population 
and study sample will be outlined.  Then a sample size calculation will take place, which serves 
to motivate the current sample size used. The source of the data for the study will be 
described. The data management will be reviewed, before finally describing the data analysis 
strategies to be employed in the paper. In concluding this section the ethical considerations 
will be outlined and a general timeline will be advised for the duration of the study. 
 
Population and Study Sample 
For the purpose of this research study, the population group is restricted to adult patients (from 
12 years and above) who have been diagnosed with sputum positive pulmonary Tuberculosis 
at KwaMashu Community Health Centre (Site 1). The sample period is inclusive of 1 January-
31 December 2015. The population is filtered by a 2 week follow at the HIV/TB clinic (Ngobani 
Clinic, Site 2). This community has an estimated HIV population of 39%(10).  
 
Sample Size and Selection of Sample 
All patients from 1 January-31 December 2015 will be used. To test if this sample size would 
suffice for this study, a brief sample size calculation is utilised for each of the objectives. 
Different sample size calculations are necessary as the sample size requirements differ per 
type of variable (qualitative and quantitative). 
 
For studies that will utilise proportions, a qualitative power calculation is necessary. Displayed 
below, a qualitative sample size formula is presented: 
 




 𝑧  is the standard normal variate where α is the probability of a type I error. For the 
purpose of this calculation, α = 0.05 will be used where Z = 1.96. 
 Ρ represents the expected proportion based on empirical evidence. 




For this study we can assume P = 0.4 and d = 0.05. Hence the required sample size for the 
is: 
1.96 ∗ 0.40 ∗ 1 0.40
0.05
368.79 ≅ 369 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
 
Sources of Data 
The primary source of data consists of notebooks and patient files recorded by the attending 
nurses at the two sites.  
 
At KwaMashu Community Health Centre initial sputum samples are collected and patients are 
screened for tuberculosis.  These screening data books contain patient demographics 
(patients name; cell phone number; date of birth), HIV status, diabetic status, date of initial 
sputum sample, date patient followed up results and if commenced on treatment. These data 
books form sample one.   
 
After receiving two weeks of treatment the patients move to the second site, the HIV/TB Clinic.  
Here the patient’s folder will be used as data sample two.  The data within these folders contain 
some of the information from sample one but also details the follow up visits, compliance to 




A primary feature of a medical study is the use of paper records as the source data. The 
inherent risk introduced from this feature can introduce both bias and incompleteness to the 
sample data set. To reduce the bias and incompleteness due to human error; a well-defined 
data management plan is necessary. This plan needs to detail the controls to be exercised 
when capturing the manual records, reviewing the captured information and cleaning the final 
dataset for analysis. 
 
In the following sections, the discussion of the data controls, treatment of incomplete records 
and cleaning of the dataset will be discussed. 
 
Data Entry 
The process of data entry is typically conducted by data capturers who are not cognisant of 
the purpose of the study or intended use of the data. As such the quality of the data captured 
can be adversely affected due to incorrect understanding of the required data types. Thus it is 
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imperative that a clear guideline is set up with respect to the capturing process. This is 
summarised below; 
 
 Two data capturers need to be utilised 
 One to transcribe the data and the other to check the transcribed data for errors 
 All missing information needs to be typed as NULL 
 The variable fields need to be clearly explained and labelled in the spread sheets. 
 Formatting rules need to be applied to ensure only correct data types are captured. 
 Uncertainty regarding records need to be highlighted and escalated to the researcher. 
 Once all data is transcribed, random samples need to be drawn and rechecked by both 
the researcher and two data capturers to identify any errors or omissions. 




The aim for the data cleaning protocol is to ensure that the raw data is consistent with the 
predefined variable types. This is to ensure occurrences of data type mismatch do not occur. 
Data cleaning has two procedural methods namely; correction (through direct editing) and 
deletion of the whole record. 
 
Correction of specific categories can include recoding of characters as numbers such as “two” 
to “2”, “malee” to “male” etc. These errors could occur both from source and through data 
capturing. The aim of the data entry protocol is to ensure these errors are corrected on entry. 
A secondary error that could incur would be invalid records such as negative ages or ages 
beyond a designated band.  
 
To identify these secondary entries, it is prudent to conduct descriptive analysis of the data. 
This would include take means of the data for numerical data types, medians and modes for 
categorical data types, and in addition, the creation of five number summaries for each 
variable. This basic summary of the data will allow for an immediate overview of available data 
and assist in the identification of any outliers in the data set. These outliers will include the 
secondary errors.  
 
Data deletion, the complete removal of secondary error records, ensures that the data is 






An inherent feature of manual case records is the occurrence of missing or incomplete 
records. As highlighted by Worster, two methods are typically employed in response to this 
phenomenon. The first is that of case deletion where the record is deleted from the dataset. 
The disadvantage from this method, is the sample size is reduced (the power as well) and 
bias may be introduced into the population. The alternative method frequently used (and the 
one employed in this study) is multiple imputation. This method utilises the existing data points 
to estimate the variance and covariances of the missing observations to generate parameter 
estimates and confidence intervals (29). 
 
Data Analysis Strategies 
The analysis of the data is required to be subdivided into two separate areas of focus. The 
necessity of this division stems from the underlying objectives forming two separate groups; 
the first covers the compliance of the clinics with Clinical Guidelines while the second deals 
with HIV and TB proportions. 
 
The general analysis for a medical study consists of the analysis of categorical and numerical 
information. The inherent nature of these data types, lead to the calculation of proportions. To 
test if significant differences exist between proportions, a Chi Squared test is typically utilised. 
In conjunction to this test, to identify if there are differences in the means of the sample 
populations, a T-Test is typically employed. The combination of these two types of Hypothesis 
tests is sufficient to cover the scope of this study. 
 
If the interest extends beyond proportional and mean comparison, and instead focuses on 
generating models that allow for the prediction of compliance; a regression model can be fitted. 
The regression model, models the relationship between a dependent variable and a list of 
independent variables in an attempt to explain the dependent variable. A multivariable 
regression model is termed a multiple regression model. This term is typically applied when 
the dependent variable is non-categorical or numeric. In a medical study however the variable 
of interest tends to be binary in nature. A regression model where the dependent variable is 
binary or categorical is termed a Logistic Regression Model.  
 
Logistic Regression 
One of the principal methods to be employed for the data analysis section is that of regression 
analysis. The intent is to develop a model that will allow for functional classification of sites in 
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terms of their compliance with clinic guidelines. To predict this binary response, a logistic 
model is necessary. 
 
We have a dependent variable Y = compliance status 
Y = 1 if compliant 
Y = 0 if non-compliant 
We are interested in the P(compliance) = P(Y=1) = p. Of particular interest to us, is how this 
dependent variable relates to the independent variables in the study. A typical linear 
regression model of form: 
𝑝  𝛽 𝛽 𝑥 
 
Is not appropriate as for 𝛽 values can lie between (-∞,∞) where as we want p to be between 
0 and 1; the data that is analysed is not normally distributed and as such the normal theory 
underlying linear models is not appropriate and the variance for each individual is not constant. 
These reasons motivate the use of a logistic regression model where a transformation to “p” 
is applied: 
 









𝛽 𝑥 𝛽  
Where the “i" subscript refers to each individual. The logistic regression model forms part of 
the generalized linear model family. The underlying distribution for this model is the binomial 
distribution. 
 
After fitting the model and estimating the beta parameters, the significance can be tested. 
Either a confidence interval approach or standard T-Test can be used. With the null hypothesis 
of 𝛽 0, the ratio of 𝛽 /𝑠𝑒 𝛽  can be computed and compared the relevant critical value. 
To compute a confidence interval at the 95% interval; 
 
𝛽 ∓ 1.96 𝑠𝑒 𝛽  
 




𝛽 log 𝑂𝑅  






Point-Biserial Correlation:  
 
A hypothesis question has been formulated, ‘The Staff at KwaMashu CHC lack the knowledge 
of the Gene Xpert MTB/RIF algorithm and are therefore not compliant to the National 
tuberculosis GXP guidelines.’ This hypothesis will allow for the scope of the study to be 
correctly defined. The results from the questionnaires will permit motivation for conducting the 
study and aid in proving the specific aims. The hypothesis result would either be confirmatory 
or investigative. The correlation with the study results will help verify the study aims and form 
part of the quality improvement project. The hypothesis results will be correlated to the study 
results, this is to be tested by investigating the linear relationship between a questionnaire 
form (numeric variable) and the compliance factor (dichotomous variable). 
A typical correlation cannot be used as it measures the relationship between two continuous 
variables. To allow for the presence of a binary variable, the adjusted correlation coefficient of 
the Point-Biserial Correlation is warranted. We will term this coefficient as 𝑟 . In a typical 
correlation format, -1 and 1 represent the range of values the coefficient can take. Where -1 
and 1 represent perfect negative and positive correlation (and 0 represents no association). 
The Point-Biserial Correlation coefficient like typical Pearson Correlation has two assumptions 
which need to be tested before the application of the technique namely; the continuous 
variable is normally distributed and homoscedasticity. It should be noted that an alternative to 
test the relationship between the above mentioned variables is a univariant logistic regression. 
𝑟 𝑀 𝑀 ∗ 𝑝 𝑝 /𝑍𝑆  
 Where 𝑀 and 𝑀  are the means of the two groups. 
 
 Where 𝑝 and 𝑝  are the proportions of the two groups of the total. 
 
 Where 𝑆  is the standard deviation of the continuous variable as a whole. 
 
 Where Z is the Z-score for 𝑝  or 𝑝  whichever is smaller. 
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Ethics and Human Subjects Issues 
 
1. Scientific validity.  
There is a paucity of data concerning the compliance to sputum guidelines, this study is not 
only scientifically valid but also a means of quality improvement. 
2. Confidentiality 
This is a retrospective chart review study. There will be no patient contact. Patients will be 
captured on the data collection tool using only their registration numbers. 
The questionnaire conducted is also anonymous. 
3. Informed Consent 
Informed consent was not obtained for the study as it is a retrospective chart review. Informed 
consent was however obtained at the time of HIV testing. 
4. Conflict of Interest 




 The 2 year degree of the MMED SCI was registered in March 2016.  
 Proposal completion March 2016-August 2016 
 Project Converted to MMED January 2017 (Registrar Post Internal Medicine) 
 Submission to Biomedical Research Ethics Committee (BREC) for Ethics review  
February 2017 
 Data Collection: June 2017-February 2018 
 Data Analysis March 2018 





LIMITATIONS OF THE STUDY 
 
Data limitations are imposed from censored data points. This will involve both patients who 
are lost to follow up and due to human error through documentation and record keeping. Bias 
can be introduced into the data from the fact that only one clinic is examined-this constricts 
the sample size and demographics of the population. 
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PUBLIC HEALTH SIGNIFICANCE 
 
Tuberculosis continues to be a serious health concern both locally in South Africa and 
internationally. Many studies have been published with regard to the compliance to 
Tuberculosis treatment guidelines, however little is known about compliance to the GeneXpert 
sputum guidelines. Sputum collection forms the corner stone of TB diagnosis and further 
management. According to the South African guidelines, Gene-Xpert forms the initial 
investigation for the diagnosis of TB with South Africa having the largest Gene-Xpert rollout 
programme in the world. However, there currently is a paucity of data regarding compliance 
to the national Gene-Xpert sputum guidelines. Further research is required on this topic to 
help improve the diagnosis and management of patients with suspected TB. It is hoped that 
the data from this study will improve TB diagnosis and management at the local community 
health centre in KwaMashu a township in Durban, South Africa. This area is currently a hotbed 
for TB and HIV co-infection. This study will help identify compliance to the GeneXpert 
algorithm by staff at the health centre. This would then improve the diagnosis and 
management of patients with TB. This study could then serve as a quality improvement project 
that can hopefully be extrapolated onto a bigger scale and promote similar studies to be 






1. Don L. Lango (ed.), Anthony S. Fauci (ed.), Dennis L. Kasper (ed.), Stephen L. Hauser 
(ed.), J. Larry Jaameson (ed.), Joseph Loscalzo (ed.). Harrisons’ Principals of Internal 
Medicine. Volume 1. 18th Edition. USA: McGraw Hill Companies; 2012 p[ ] 
2. WHO. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the 
diagnosis and screening of active tuberculosis in people living with HIV. WHO. Report 
Number: 2015,25. 
3. CDC. Introduction to the core curriculum on tuberculosis: What a clinician should know. 
Chapter 2. 6th Edition. CDC. 2013. 
4. Connie A Haley. Extrapulmonary tuberculosis. [Presentation]. University of Florida, 
Southeast National Tuberculosis Centre. September 2013. 
5. Gerald Friedland, Anthony Harries, David Coetzee. Implementation Issues in 
Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies. The Journal 
of Infectious Diseases. 2007; 196(supplement 1): S114-S123. Available From: 
http://jid.oxfordjournals.org/content/196/Supplement_1/S114.full [Accessed 3 June 
2016] 
6. Charles W. Schmidt. Linking TB and the Environment: An Overlooked Mitigation 
Strategy. Environmental Health Perspectives. 2008 Nov; 116(11): A478–A485. 
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592293/ [Accessed 3 
June 2016] 
7. David Coetzee, Katherine Hilderbrand, Eric Goemaere, Francine Matthys, Marleen 
Boelaert. Integrating tuberculosis and HIV care in the primary care setting in South 
Africa. Tropical Medicine and International Health. 2004; 9(6): A11–A15. Available 
From: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2004.01259.x/full 
[Accessed 7 June 2016] 
8. WHO. Global tuberculosis report 2015. WHO. Report number: 20, 2015. 
9. Annabel Kanabus. TBFacts.org: TB Statistics for South Africa – National & provincial. 
Available from: http://www.tbfacts.org/tb-statistics-south-africa/ [Accessed 8 June 
2016] 
10. Martin Gabela, Nicky Manivasen, Melanie Dazel, Ronald Dukie. District Health Plan 
2015/2016 Ethekwini Health District KwaZulu-Natal. Department of Health: Province 
of KwaZulu-Natal. 2015 
11. Ethekwini Municipality. Inanda, Ntuzuma, KwaMashu (INK) Nodal Economic 
Development Profile KwaZulu Natal. Department: Provincial and Local Government, 
Republic of South Africa. 2006 
60 
 
12. Department of Health, Republic of South Africa. National Tuberculosis Management 
Guidelines 2014. ISBN: 978-1-920031-82-4, 2014. 
13. Gavin J Churchyard, Wendy S Stevens, Lerole D Mametja, Kerrigan M McCarthy, 
Violet Chihota, Mark P Nicol, et al. Xpert MTB/RIF versus sputum microscopy as the 
initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South 
African roll-out of Xpert MTB/RIF. The Lancet Global Health. 2015; 3(8): e450–e457. 
Available from: http://www.thelancet.com/journals/langlo/article/PIIS2214-
109X(15)00100-X/fulltext [Accessed 14 June 2016] 
14. Sebaka Molapo, Elizabeth Prentice, Linda Erasmus. GeneXpert MTB/RIF Frequently 
asked questions. National Health Laboratory Services. 2012. Available from: 
http://www.nhls.ac.za/assets/files/GeneXpert%20brochure.pdf [Accessed 14 June 
2016] 
15. Kuldeep Singh Sachdeva, Neeraj Raizada,  Achuthan Sreenivas, Anna H. van't 
Hoog, Susan van den Hof, Puneet K. Dewan,et al. Use of Xpert MTB/RIF in 
Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB 
Case Finding in India. PLOS One. 2015; 10(5): e0126065. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440647/pdf/pone.0126065.pdf 
[Accessed 18 June 2016] 
16. Saul N Weingart. Implementing practice guidelines: easier said than done. Israel 
Journal of Health Policy Research. 2014; 3(20). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070343/ [Accessed 10 July 2016] 
17. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review 
of theoretic concepts, practical experience and research evidence in the adoption of 
clinical practice guidelines. Canadian Medical Association Journal. 1997; 157(4): 
408–416. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1227916/pdf/cmaj_157_4_408.pdf 
[Accessed 10July 2016] 
18. Cabana MD, Rand CS, Powe PR, Wu AW, Wilson MH, Abboud PC, Rubin HR. Why 
don’t physicians follow clinical practice guidelines? A framework for improvement. 
Journal of the American Medical Association. 1999; 282(15):1458-1465. Available 
from: http://jama.jamanetwork.com/article.aspx?articleid=192017 [Accessed 10 July 
2016] 
19. National Health Laboratory Service. GeneXpert MTB/RIF progress report April 2015. 
NationalHealth Laboratory Service. 2015 Available from: 
http://www.nhls.ac.za/assets/files/GeneXpert%20Progress%20Report%20April%202
015%20Final.pdf [Accessed 20 July 2016] 
61 
 
20. Frederick AD Kaona, Mary Tuba, Seter Siziya, Lenganji Sikaona. An assessment of 
factors contributing to treatment adherence and knowledge of TB transmission 
among patients on TB treatment. BMC Public Health. 2004; 4(68). Available from:  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC545081/ [Accessed 20 July 2016] 
21. Nandzumuni V. Maswanganyi, Rachel T. Lebese, Ntsieni S. Mashau, Lunic B. 
Khoza. Patient-perceived factors contributing to low tuberculosis cure rate at Greater 
Giyani healthcare facilities.  Health SA Gesondheid. 2014; 19(1): 1-8. Available from: 
http://www.hsag.co.za/index.php/HSAG/article/view/724/986 [Accessed 20 July 2016] 
22. Cramm, J.M., Finkenflügel, H.J.M., Møller, V. & Nieboer, A.P., 2010. TB Treatment 
initiation and adherence in a South African community influenced more by 
perceptions than knowledge of tuberculosis. BMC Public Health. 2010; 10:72. 
Available from: http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-
2458-10-72 [Accessed 20 July 2016] 
23. Wendy Stevens. Beyond Implementation: Health systems strengthening and focus 
on high risk populations 2011-2014. [Presentation] WHO Geneva, Switzerland. 2 
May 2014. Available from: 
http://www.stoptb.org/wg/gli/assets/documents/M6/Stevens%20-
%20Nationwide%20roll%20out%20of%20Xpert%20as%20initial%20diagnostic%20te
st.pdf [Accessed 21 July 2016] 
24. Fabrice Nembot Djouma, Michel Noubom, Jérôme Ateudjieu, Hubert Donfack. Delay 
in sputum smear conversion and outcomes of smear-positive tuberculosis patients: a 
retrospective cohort study in Bafoussam, Cameroon. BMC Infectious Diseases. 
2015;15:139. Available From: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381415/ [Accessed: 21 July 2016] 
25. Khalid Bouti, Mohammed Aharmim, Karima Marc, Mouna Soualhi, Rachida Zahraoui, 
Jouda Benamor, et al. Factors Influencing Sputum Conversion among Smear-
Positive Pulmonary Tuberculosis Patients in Morocco.  ISRN Pulmonology. 2013; 
2013: 5 pages. Available from: 
http://www.hindawi.com/journals/isrn/2013/486507/cta/ [Accessed 21 July 2016] 
26. Mbazi SenkoroEmail author, Sayoki G Mfinanga, Odd Mørkve. Smear microscopy 
and culture conversion rates among smear positive pulmonary tuberculosis patients 
by HIV status in Dar es Salaam, Tanzania. BMC Infectious Diseases. 2010; 10(210). 
Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-
10-210 [Accessed 21 July 2016] 
27. R. Singla, M. M. Osman, N. Khan, N. Al-Sharif, M. O. Al-Sayegh, and M. A. Shaikh. 
Factors predicting persistent sputum smear positivity among pulmonary tuberculosis 
patients 2 months after treatment. International Journal of Tuberculosis and Lung 
62 
 
Disease. 2003; 7(1): 58–64. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12701836 [Accessed 21 July 2016] 
28. Department: Health, Province of KwaZulu Natal. KWAMASHU COMMUNITY HEALTH 
CENTRE. Available from: http://www.kznhealth.gov.za/kwamashuchc.htm [Accessed 
10 June 1016] 
29. Andrew Worster, Ted Haines. Advanced Statistics: Understanding Medical Record 
Review (MRR) Studies. Academic Emergency Medicine. 2004;11(2): 187-192. 
Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1553-
2712.2004.tb01433.x/pdf [Accessed 5 June 2016] 
30. Marie Muller. Quality Improvement in health care-a fundamental analysis and South 
African Perspective.Curationis.1996;19(4): 67-74. Available from: 
http://www.curationis.org.za/index.php/curationis/article/view/1340 [Accessed 12 July 
2016] 
31.  Vera Scott, Virginia Azevedo, Judy Caldwell. Improving access and quality of care in 
a TB control programme. SAMJ. 2012;102(11). Available from: 





Appendix 1: Questionnaire 
PLEASE CIRCLE THE CORRECT ANSWER 
1. What is the initial sputum test you order for patients suspected to have Tuberculosis 
(TB)?  
(A. GXP or B. AFB’s) 
 
2. If your specimen for GXP is unsuccessful what sputum specimen do you send? 
(A. GXP or B. AFB’s) 
 
3. If the initial sputum test is GXP positive what is the second sputum test you send? 
(A. GXP or B. AFB’S) 
 
4. Resistance to which drug/s can GXP pick up? 
(A.  Rifampicin or  B. Isoniazid or C. Both) 
 
5. At which intervals do you repeat sputum tests while on treatment? 
(A. 2 months or B. 5 months or C. Both or D. 3 months) 
 
6. With regards to follow up sputum, while on treatment, which sputum test do you order? 
(A. GXP or B. AFB’s) 
 
7. In a HIV positive patient who is suspected of having TB and the GXP sputum test is negative, 
what is the next test to be ordered? 
 (A. GXP or B. AFB’S or C. Culture + LPA/DST) 
 
8. If a patient is GXP positive and resistant to rifampicin, which sputum tests do you order? 
 (A. GXP or B. AFB’S or C. Culture + LPA/DST or D. Both B and C) 
 
*GXP (Gene Xpert); AFB (Acid Fast Bacilli); LPA/DST (Line Probe Assay/Drug Sensitivity Testing)  
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My name is Dr. S Pillay. I am a medical doctor working in the department of internal 
medicine at King Edward VIII Hospital. My contact number is 0313603111, Email: 
sarush.pillay@gmail.com . 
 
You are being invited to consider participating in a study that involves in part a research 
questionnaire, based on your knowledge of the sputum Gene Xpert Algorithm.  The aim of 
this research is to evaluate the compliance to the Gene Xpert algorithm at your clinic. The 
study is expected to enroll 30 staff members from the KwaMashu Community Health Centre. 
It will involve an 8 question questionnaire. It is an anonymous questionnaire. The 
questionnaire will take a few minutes of your time to complete and thereafter there is no 
further involvement on your part which is required.  
  
We hope that this study will improve compliance to the sputum Gene Expert guidelines. This 
will help improve the diagnosis and management of patients suspected of having 
tuberculosis (TB). This study could then serve as a quality improvement project that can be 
implemented in other health facilities in South Africa.  
 
This study has been ethically reviewed and approved by the UKZN Biomedical research Ethics 
Committee (approval number_____). 
 
In the event of any problems or concerns/questions you may contact the researcher at Tel: 
031 360 3111, Email: sarush.pillay@gmail.com or the UKZN Biomedical Research Ethics 
Committee, contact details as follows:  
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
Your participation in this research is voluntary; you may withdraw your participation at any 
point. In the event of refusal/withdrawal of participation you will not incur any penalty or 
loss. Participants who are found to have duplicated other participants’ answers to the 
questionnaire will be excluded from the study. No costs will be incurred by participants as 
a result of participation in this study. 
 
 
The questionnaire is anonymous with no participant identifiers. The answers to the questions 
will be captured in an excel document with no participant identifiers. This data will then 













I____________________have been informed about the study entitled: A Retrospective 
review of compliance to the national Tuberculosis management guidelines: Gene Xpert 
MTB/RIF algorithm in a primary health care center in Kwa-Zulu Natal, South Africa by Dr. 
S Pillay. 
 
I understand the purpose of the study. 
 
I have been given an opportunity to ask questions about the study and have had answers to 
my satisfaction. 
 
I declare that my participation in this study is entirely voluntary and that I may withdraw at 
any time without any loss. 
 
 
If I have any further questions/concerns or queries related to the study I understand that I 
may contact the researcher at Tel: 031 360 3111, Email: sarush.pillay@gmail.com. 
 
If I have any questions or concerns about my rights as a study participant, or if I am 
concerned about an aspect of the study or the researchers then I may contact: 
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 




____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 
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Appendix: 3 Additional statistical analysis 
 
A. DESCRIPTIVE STATISTICS 
Demographic Characteristics – Complete dataset (N = 596) 
Variable Category Frequency – n (%) 
Age Below 20 36 (6.04) 
 20 - 29 192 (32.21) 
 30 - 39 204 (34.23) 
 40 - 49 95 (15.94) 
 50 - 59 45 (7.55) 
 Above 60 24 (4.03) 
Gender Male 381 (63.93) 
 Female 215 (36.07) 
HIV Status Positive 360 (60.40) 
 Negative 168 (28.19) 
 Unknown 68 (11.41) 
On HAART No 326 (54.70) 
 Yes 250 (41.95) 
 Unknown 20 (3.36) 
 
Demographic Characteristics – Defaulted Cohort (N = 162) 
Variables Category Frequency – n (%) 
Age Below 20 10 (6.17) 
 20 – 29 58 (35.80) 
 30 – 39 57 (35.19) 
 40 – 49 24 (14.81) 
 50 – 59 10 (6.17) 
 Above 60 3 (1.85) 
Gender Male 100 (66.67) 
 Female 54 (33.33) 
HIV Status Positive 109 (67.28) 
 Negative 36 (22.22) 
 Unknown 17 910.49) 
On HAART No 87 (53.70) 
 Yes 68 (41.98) 
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 Unknown 7 (4.32) 
GXP Procedure Done 156 (96.30) 





B. RESULTS BASED ON THE OBJECTIVES 
 
 The number of patients who are Gene Xpert Positive who get a smear at base. 
 
Gene Xpert Category Frequency – n (%) 
Procedure (n =596) Done 572 (95.97) 
 Not done 24 (4.03) 
Results (n = 572) Unsuccessful 4 (0.70) 
 Detected 558 (97.55) 
 Undetected 10 (1.75) 
 
  Smear Microscopy result  
Gene Xpert Category Negative Positive Unknown Total 
Procedure (n =596) Not done 4  19  1  24 (4.03) 
 Done 232  232  108  572 (95.97) 
Results (n = 572) Unsuccessful 2  0  2  4 (0.70) 
 Detected 222  231 105 558 (97.55) 
 Undetected 8 1 1 10 (1.75) 
 
 The proportion of patients who have sputum collected at two months and 5 months. 
 The proportion of patients who have sputum collected at two months and 5 months who 
undergo smear conversion or develop drug resistance Tuberculosis 
 
Smear Microscopy Category Frequency – n (%) 
2 Months (n = 596) No 208 (34.90) 
 Yes 388 (65.10) 
5 Months (n = 596) No 337 (56.54) 
 Yes 257 (43.12) 




Sputum conversion Category Frequency – n (%) 
2 Months (n = 546) No 162 (29.67) 
 Yes 384 (70.33) 
5 Months (n = 458) No 59 (12.88) 
 Yes 399 (87.12) 
 
  Smear Microscopy (2 Months) 
Sputum Conversion Category No Yes Total 
2 Months Yes 195 189 384 (70.33) 
 No 0 162 162 (29.67) 
 
 
  Smear Microscopy (2 Months) 
Sputum Conversion Category No Yes Total 
5 Months Yes 198 201 399 (87.12) 
 No 10 49 59 (12.88) 
 
  Smear Microscopy (5 Months) 
Sputum Conversion Category No Yes Unknown Total 
5 Months Yes 206 192 1 399 (87.12) 
 No 2 57 0 59 (12.88) 
 
 
  MDR TB 
Sputum Conversion Category No Yes Total 
2 Months Yes 338 46 384 (70.33) 
 No 152 10 162 (29.67) 
 
 
  MDR TB 
Sputum Conversion Category No Yes Total 
5 Months Yes 355 44 399 (87.12) 





 The proportion of patients diagnosed GXP positive Tuberculosis who are co-infected with 
HIV. 
 The number of HIV co-infected patients who achieve smear conversion or develop 
drug resistant Tuberculosis. 
 
 GXP Procedure 
HIV Status Not Done Done Total (%) 
Positive 12 348 360 (60.40) 
Negative 10 158 168 (28.19) 
Unknown 2 66 68 (11.41) 
Total 24 572 596 (100.00) 
 
 GXP Result 
HIV Status Unsuccessful Detected Undetected Total (%) 
Positive 4 335 9 348 (60.84) 
Negative 0 158 0 158 (27.62) 
Unknown 0 65 1 66 (11.54) 
Total 4 558 10 572 (100.00) 
 
 Sputum conversion – 2 Months 
HIV Status Yes No Total (%) 
Positive 244 89 333 (60.99) 
Negative 90 62 152 (27.84) 
Unknown 50 11 61 (11.17) 
Total 384 162 546 (100.00) 
 
 
 Sputum conversion – 5 Months 
HIV Status Yes No Total (%) 
Positive 240 30 270 (58.95) 
Negative 104 22 126 (27.51) 
Unknown 55 7 62 (13.54) 






 MDR TB 
HIV Status Yes No Total (%) 
Positive 42 318 360 (60.40) 
Negative 14 154 168 (28.19) 
Unknown 2 66 68 (11.41) 






















































C. SPUTUM CONVERSION – 2 MONTHS 
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D. SPUTUM CONVERSION – 5 MONTHS 
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E. MULTI DRUG RESISTANT- TB 
a. By HIV Status 
 
MDR – TB grouped by HIV Status, based on the number of days from baseline. 
 Evidently, it’s only patients who were HIV+ that developed MDR-TB, from the baseline day. 
 
b. By Gender 
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